Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy
Open Access
- 16 March 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (4) , ofaa095
Abstract
Background: Direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) result in initial cure rates of 95% to 99% and re-treatment cure rates of 95%. Nevertheless, given the sheer magnitude of infected persons, some will ultimately fail multiple DAA therapies, and re-treatment of these persons has not been adequately studied. Methods: We evaluated treated an HIV-infected man with cirrhosis from genotype 1b HCV who had failed 3 DAA regimens. Results: We treated and cured our “particularly difficult-to-cure” patient with sofosbuvir plus glecaprevir/pibrentasvir plus ribavirin for 24 weeks. We discuss the literature on potential biological factors behind his treatment failures such as lack of HCV seroconversion during his infection course, and multiple failures of hepatitis B seroconversion after vaccination, and the rationale for choosing his curative salvage regimen. Discussion: There are no clinical trials-proven re-treatment regimens for “particularly difficult-to-cure” patients. Multiple patient- and virus-related factors that do not affect cure rates in treatment-naive patients may need to be considered in choosing a re-treatment regimen for these patients. These regimens may need to include combinations drugs that are not available in single-tablet form, addition of ribavirin, and longer durations of treatment than standard.Keywords
This publication has 28 references indexed in Scilit:
- Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1New England Journal of Medicine, 2015
- O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeksJournal of Hepatology, 2015
- Hepatitis C Virus (HCV) Antibody Dynamics Following Acute HCV Infection and Reinfection Among HIV-Infected Men Who Have Sex With MenClinical Infectious Diseases, 2014
- Importance of HCV genotype 1 subtypes for drug resistance and response to therapyJournal of Viral Hepatitis, 2014
- Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCVAIDS, 2009
- Factors Associated with Seronegative Chronic Hepatitis C Virus Infection in HIV InfectionClinical Infectious Diseases, 2007
- Undetectable Plasma HIV RNA Load Predicts Success after Hepatitis B Vaccination in HIV-Infected PersonsClinical Infectious Diseases, 2005
- Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double doseVaccine, 2005
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected PatientsNew England Journal of Medicine, 2004
- Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected PersonsNew England Journal of Medicine, 2004